H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock. Currently trading at $11.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback